Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biotheus to Develop Antibodies With Bitterroot for Cardio-Immunology

publication date: Feb 28, 2024

Zhuhai’s Biotheus formed a multi-year collaboration with Bitterroot Bio of Palo Alto to discover novel approaches that modulate the immune system and regulate inflammation, with the goal of addressing atherosclerosis and other potentially fatal cardiovascular conditions. Biotheus will design novel monoclonal and multi-specific antibodies using its proprietary platforms. Bitterroot will add its expertise in cardiovascular medicine and biology to the partnership. Bitterroot is a cardio-immunology company that focuses on the impact of the immune system on cardiovascular health. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital